Evaluating bone mineral metabolism markers as cardiovascular risk factors in chronic kidney disease patients
Official title: New Biomarkers of Bone and Mineral Metabolism as Risk Factors for Morbidity/Mortality in Chronic Kidney Disease Patients Not Requiring Dialysis
Run by University Hospital, Montpellier · NCT02808572 · Data updated 2026-11-12
This study is testing if certain bone health markers can help predict heart problems in people with chronic kidney disease over seven years.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 95 Years |
| Sex | All |
| Enrollment | 250 (estimated) |
| Sponsor | University Hospital, Montpellier Academic / other |
| Locations | 7 sites (Montpellier and 6 other locations) |
| Status | Recruiting |
| Started | March 12, 2013 |
| Main results expected | March 2024 |
| Study ends | June 2031 |
| Registry record updated | January 4, 2022 |
| Trial ID | NCT02808572 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are patients with chronic kidney disease who are not on dialysis and have provided written consent.
✕Probably not a fit
Patients who are pregnant or require dialysis therapy will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study aims to assess the relationship between specific bone mineral metabolism markers, such as osteoprotegerin and fibroblast growth factor 23, and the occurrence of cardiovascular events in patients with chronic kidney disease over a 7-year follow-up period. By measuring plasma levels of these markers and vascular calcification scores, the study seeks to identify potential cardiovascular risks associated with chronic renal failure. The findings could help in understanding how bone metabolism influences cardiovascular health in this patient population.
Why it matters
Potential benefit: If successful, this study could lead to improved risk assessment and management strategies for cardiovascular events in patients with chronic kidney disease.
How similar studies have gone: While the specific approach of this study may be novel, there is existing research indicating that biomarkers related to bone metabolism can influence cardiovascular risk in chronic kidney disease patients.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patient who has signed the written consent form * Patient with chronic renal failure defined by glomerular filtration rate (GFR) but without dialysis therapy Exclusion Criteria: * Pregnancy * Patient with chronic renal failure requiring dialysis therapy
Where it's running
-
Aider
Montpellier, France Recruiting -
CHU Montpellier, Endocrinology department
Montpellier, France Recruiting -
CHU Montpellier, Nephrology department
Montpellier, France Recruiting -
CHU Montpellier, Cardiology department
Montpellier, France Active not recruiting -
CHU Montpellier, Intensive care unit
Montpellier, France Active not recruiting -
CHU Montpellier, Internal medicine department
Montpellier, France Active not recruiting
Show 1 more location
-
Aider
Saint-Jean-de-Védas, France Not yet recruiting
Study contacts
- Principal investigator: Jean-Paul CRISTOL, Prof — CHU Lapeyronie, Department of Biochemistry and Hormonology, Montpellier, FRANCE
- Study coordinator: Jean-Paul CRISTOL, Prof
- Email: jp-cristol@chu-montpellier.fr
- Phone: +33(0)4 67 33 83 15
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Observational look at how Kremezin works in adults with advanced chronic kidney disease
This study tests whether Kremezin helps adults with advanced kidney disease when used as part of routine care, by tracking safety and kidney function over up to 48 weeks.
-
Kidney and Heart Health in Adults with Type 2 Diabetes and CKD Treated with Semaglutide in China
This study tests whether semaglutide injections help kidney and heart health in adults with type 2 diabetes and chronic kidney disease.
-
High BMI and periodontitis in Thai adults under 60
This study tests how common high BMI and periodontitis are among Thai adults aged 18–59 and what factors are linked to them.
-
Optimised Cardio-Renal Care for CKD and heart disease
This study tests whether a specialised Cardio-Renal Clinic can improve heart and kidney health and quality of life for adults with chronic kidney disease and cardiovascular disease.
-
NMR-based Risk Test and Digital Health Support for midlife adults in Eloisa
This study tests whether an NMR metabolomics risk test can guide tailored digital health programs for midlife adults at risk of diabetes, heart disease, stroke, kidney disease, or fatty liver.
-
Arterial stiffness in children and young people with CKD and hypertension
This study will test whether arterial stiffness is higher in children and young people with chronic kidney disease and high blood pressure compared with their peers, using a one-time assessment and follow-up for those with high BP.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.